VivoSeq
Psychiatry

Bipolar II Disorder

10

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Bipolar II Disorder is an early-stage landscape with 10 programs across 3 companies. The most active players are Neumora Therapeutics, Inc., COMPASS Pathways, AbbVie. 4 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

6/100

Mech. Concentration

17/100

Completion Rate

75/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

Neumora Therapeutics, Inc.

1 program

Phase 2COMPASS Pathways logo

COMPASS Pathways

1 program

Phase 3AbbVie logo

AbbVie

2 programs

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

7

clinical trials

Completed3 · 43%
Unknown status1 · 14%
Not yet recruiting1 · 14%
Active, not recruiting1 · 14%
Terminated1 · 14%

Clinical Trials

Trial Activity

7 trials

Psilocybin Therapy for Depression in Bipolar II Disorder
Active, not recruiting·UUniversity of California, San Francisco·Phase 2·NCT05065294·14 enrolled
Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder
Not yet recruiting·—·Phase 3·NCT06943573·90 enrolled
Escitalopram as a Mood Stabilizer for Bipolar II Disorder
Completed·TThe University of New South Wales·Phase 2·NCT00156325·10 enrolled
To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.
Completed·NNeumora Therapeutics, Inc.·Phase 2·NCT06429722·18 enrolled
Open-Label Comparative Study of Risperidone Versus Olanzapine Versus Quetiapine for Mania in Children and Adolescents With Bipolar I and Bipolar II Disorder
Completed·MMassachusetts General Hospital·Phase 4·NCT00182013·106 enrolled
Phase 2 Clinical Trial of GH001 in Bipolar II Disorder
Terminated·GGH Research Ireland Limited·Phase 2·NCT05839509·6 enrolled
add-on Low Dose Memantine in Middle-to-old Aged Bipolar II Disorder Patients
Unknown status·NNational Cheng-Kung University Hospital·Phase 2/3·NCT04035798·120 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)